Woodline Partners
VC Fund
San Francisco, United States
Woodline Partners is a private equity firm that focuses on the healthcare and technology sectors. The firm was founded in 2018 and is based in San Francisco, California, United States.
- Total investments:
- 83
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Woodline Partners invests in
BiotechnologyHealth CareTherapeuticsMedicalPharmaceutical
Stages Woodline Partners invests in
Post-IPO EquitySeries BSeries CSeries ASeries D
Countries Woodline Partners invests in
United StatesUnited KingdomGermanyChinaJapan
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Matthew Katten
|
|||
|
Andrew Pizzi
|
|||
|
Christopher Todd
|
|||
|
Matthew Hooker
|
|||
|
Mike Rockefeller
|
Investment Focus
Industry
- Biotechnology 37 (45%)
- Health Care 24 (29%)
- Therapeutics 17 (20%)
- Medical 13 (16%)
- Pharmaceutical 13 (16%)
Stage
- Post-IPO Equity 22 (27%)
- Series B 12 (14%)
- Series C 6 (7%)
- Series A 4 (5%)
- Series D 3 (4%)
Country
- United States 40 (48%)
- United Kingdom 3 (4%)
- Germany 2 (2%)
- China 1 (1%)
- Japan 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Matthew Katten
Portfolio Manager
|
Portfolio Manager | Total investments: 1 | Find email | |
|
Andrew Pizzi
Portfolio Manager
|
Portfolio Manager | Total investments: 1 | Find email | |
|
Christopher Todd
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Matthew Hooker
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
Mike Rockefeller
Co-founder & Co-Chief Investment Officer
|
Co-founder & Co-Chief Investment Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rapalogix Health
|
Rapalogix Health is a biotechnology company. | $20M / Series A / Jun 23, 2026 | |
Cuprum Metals
|
Cuprum Metals exclusive technology uses cutting-edge leaching methods to extract untapped copper deposits with the highest, fastest recovery rates and the least amount of environmental effect. | $19.4M / Series A / Jun 17, 2026 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
Climb Bio
|
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M / Post-IPO Equity / Apr 28, 2026 | |
Sagimet Biosciences
|
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M / Post-IPO Equity / Apr 27, 2026 | |
Egetis Therapeutics
|
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $38.3M / Post-IPO Equity / Apr 21, 2026 | |
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $400M / Post-IPO Equity / Feb 13, 2026 | |
Skyryse
|
Skyryse is an aerospace technology company that develops pilot assistance and autonomous flight systems designed to support safer, more accessible helicopter operations. The company’s technology integrates flight control software, sensors, and interface systems that help pilots execute complex maneuvers with enhanced precision and situationalawareness, particularly in challenging environments such as urban, offshore, or emergency response missions. Skyryse provides solutions that automate key phases of flight, including takeoff, navigation, and landing, by translating high-level inputs into coordinated control actions that align with aircraft performance and safety parameters. The company also works with OEMs, operators, and regulatory partners to certify and deploy its systems within existing rotorcraft platforms, enabling integration with avionics, mission planning, and training workflows. Its platform supports real-time data processing, redundancy management, and human-machine interaction design to assist crews while maintaining compliance with aviation safety standards. Skyryse engages with technical teams and stakeholders across civil, commercial, and public safety aviation sectors to advance adoption of automated flight capabilities that enhance operational consistency and pilot effectiveness. | $300M / Series C / Feb 03, 2026 | |
ProMIS Neurosciences
|
ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).It was founded in 2004 and headquartered in Toronto,Canada. | $75M / Post-IPO Equity / Jan 30, 2026 | |
Mirador Therapeutics
|
Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases using an integrated discovery and development platform. The company’s Mirador360 engine combines human genetics, multi-modal data, and analytical tools to identify therapeutic targets, support patient stratification, and inform drug design. Itsofferings include research programs and pipeline assets aimed at conditions such as chronic inflammation and tissue fibrosis. Mirador Therapeutics works with scientific and medical stakeholders to advance targeted therapeutic candidates through preclinical and clinical development. | $250M / Series B / Jan 12, 2026 | |
| See all 83 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Woodline Partners invest in?
Woodline Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 83 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Woodline Partners?
Public channels for Woodline Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Woodline Partners?
The team at Woodline Partners includes Matthew Katten (Portfolio Manager), Andrew Pizzi (Portfolio Manager) and Christopher Todd (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
